Effect of nitric oxide synthase (NOS) inhibition on macro- and microcirculation in a model of rat endotoxic shock

Summary

Treatment of hemodynamic instability in septic shock often demands the administration of vasopressor agents, although these may have deleterious effects on microcirculatory homeostasis. Inhibition of nitric oxide synthase (NOS) has been suggested as an alternative therapeutic approach, as NO formation may be excessively increased in sepsis. To compare the effects of epinephrine titration, non-selective NOS inhibition by L-NMMA and selective inhibition of inducible NOS (iNOS) by 1400W on hemodynamics and on the regulation of microcirculation in a rat model of endotoxic shock, we intravenously injected endotoxin (LPS) or saline to male Wist ar rats and after 2 hours randomized LPS treated rats into four different groups that received either saline, norepinephrine, L-NMMA or 1400W (n=6 per group). Three hours after LPS administration, rats presented with severe systemic arterial hypotension (64 ± 3 vs. 115 ± 4 mmHg, p<0.001), unresponsiveness to volume treatment, lactate acidosis and a marked increase in plasmatic nitrite and nitrate levels (15 ±8 vs. 263 ± 47 µM, p<0.001). Measurement of the tissue oxygenation in the ileum mucosal layer by the Erlangen micro-lightguide spectrophotometer (EMPHO) technique demonstrated marked heterogeneity of hemoglobin saturation, with appearance of low oxygenated areas. Norepinephrine, usually stabilizing blood pressure (99 ±7 vs. 67 ±4 mmHg 60 min after infusion, p<0.01), increased lactate formation (7.9± 0.2 vs. 3.7 ± 0.5 mM, p<0.001) and drastically increased low oxygenated regions in the ileum mucosal layer. L-NMMA similarly increased blood pressure (92 ±6 vs. 67 ±4 mmHg 60 min after infusion, p<0.05), but did not enhance lactate acidosis. However, some further deterioration of mucosa oxygenation was again noted. 1400W forwarded stabilization of blood pressure (88 ± 5 vs. 67 ±4 mmHg 60 min after injection, p<0.05), reduced plasmatic nitrite and nitrate levels similar to L-NMMA, without an aggravation of lactate acidosis. In addition, mucosal oxygenation did not deteriorate in response to this agent. Thereby, we conclude that in a rat model of endotoxic shock selective iNOS inhibitors are superior to non-specific NOS inhibitors and in particular to norepinephrine for the treatment of macro-and microcirculatory abnormalities in experimental septic shock.

Keywords

Sepsis - iNOS - EMPHO - 1400W - L-NMMA - norepinephrine

• References

• 1 Nathan C, Xie QW. Nitric oxide synthases: roles, tolls, and controls. Cell 1994; 78: 915-8.
• 2 Alden KJ, Motew SJ, Sharma AC. et al. Effect of aminoguanidine on plasma nitric oxide by-products and blood flow during chronic peritoneal sepsis. Shock 1998; 09: 289-95.
• 3 Hock CE, Yin K, Yue G. et al. Effects of inhibition of nitric oxide synthase by aminoguanidine in acute endotoxemia. AmJ Physiol 1997; 272: H843-50.
• 4 Rosselet A, Feihl F, Markert M. et al. Selective iNOS inhibition is superior to norepinephrine in the treatment of rat endotoxic shock. Am J Respir Crit Care Med 1998; 157: 162-70.
• 5 Scott JA, McCormack DG. Selective in vivo inhibition of inducible nitric oxide synthase in a rat model of sepsis. J Appl Physiol 1999; 86: 1739-44.
• 6 Nava E, Palmer RM, Moncada S. The role of nitric oxide in endotoxic shock: effects of NG-monomethyl-Larginine. J Cardiovasc Pharmacol 1992; 20 Suppl: (Suppl. 12) S132-34.
• 7 Levy B, Valtier M, de Chillou C. et al. Beneficial effects of L-canavanine, a selective inhibitor of inducible nitric oxide synthase, on lactate metabolism and muscle high energy phosphates during endotoxic shock in rats. Shock 1999; 11: 98-103.
• 8 Lorente JA, Landin L, de Pablo R. et al. L-arginine pathway in the sepsis syndrome. Crit Care Med 1993; 21: 1287-95.
• 9 Petros A, Lamb G, Leone A. et al. Effects of a nitric oxide synthase inhibitor in humans with septic shock. Cardiovasc Res 1994; 28: 34-9.
• 10 Grover R, Zaccardelli D, Colice G. et al. An openlabel dose escalation study of the nitric oxide synthase inhibitor, N(G)-methyl-L-arginine hydrochloride (546C88), in patients with septic shock. Glaxo Well-come International Septic Shock Study Group. Crit Care Med 1999; 27: 913-22.
• 11 Lopez A, Lorente JA, Steingrub J. et al. Multiplecenter, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit Care Med 2004; 32: 21-30.
• 12 Garvey EP, Oplinger JA, Furfine ES. et al. 1400W is a slow, tight binding, and highly selective inhibitor of inducible nitric-oxide synthase in vitro and in vivo . J Biol Chem 1997; 272: 4959-63.
• 13 Eskandari MK, Kalff JC, Billiar TR. et al. Lipopolysaccharide activates the muscularis macrophage network and suppresses circular smooth muscle activity. AmJ Physiol 1997; 273: G727-34.
• 14 Marshall JC, Christou NV, Meakins JL. The gastrointestinal tract. The “undrained abscess” of multiple organ failure. Ann Surg 1993; 218: 111-9.
• 15 Jones SB, Romano FD. Plasma catecholamines in the conscious rat during endotoxicosis. Circ Shock 1984; 14: 189-201.
• 16 Badger AM, Olivera D, Talmadge JE. et al. Protective effect of SK&F 86002, a novel dual inhibitor of arachidonic acid metabolism, in murine models of endotoxin shock: inhibition of tumor necrosis factor as a possible mechanism of action. Circ Shock 1989; 27: 51-61.
• 17 Frank KH, Kessler M, Appelbaum K. et al. The Erlangen micro-lightguide spectrophotometer EMPHO I. Phys Med Biol 1989; 34: 1883-1900.
• 18 Hasibeder W, Germann R, Sparr H. et al. Vasomotion induces regular major oscillations in jejunal mucosal tissue oxygenation. Am J Physiol 1994; 266: G978-86.
• 19 Mayer K, Temmesfeld-Wollbruck B, Friedland A. et al. Severe microcirculatory abnormalities elicited by E. coli hemolysin in the rabbit ileum mucosa. Am J Respir Crit Care Med 1999; 160: 1171-8.
• 20 Sato N, Kamada T, Shichiri M. et al. Measurement of hemoperfusion and oxygen sufficiency in gastric mucosa in vivo. Evidence of mucosal hypoxia as the cause of hemorrhagic shock-induced gastric mucosal lesion in rats. Gastroenterology 1979; 76: 814-9.
• 21 Temmesfeld-Wollbruck B, Szalay A, Mayer K. et al. Abnormalities of gastric mucosal oxygenation in septic shock: partial responsiveness to dopexamine. Am J Respir Crit Care Med 1998; 157: 1586-92.
• 22 Leung FW, Morishita T, Livingston EH. et al. Reflectance spectrophotometry for the assessment of gastroduodenal mucosal perfusion. Am J Physiol 1987; 252: G797-G804.
• 23 Hayashi Y, Abe M, Murai A. et al. Comparison of effects of nitric oxide synthase (NOS) inhibitors on plasma nitrite/nitrate levels and tissue NOS activity in septic organs. Microbiol Immunol 2005; 49: 139-47.
• 24 Lush CW, Kvietys PR. Microvascular dysfunction in sepsis. Microcirculation 2000; 07: 83-101.
• 25 McCuskey RS, Urbaschek R, Urbaschek B. et al. The microcirculation during endotoxemia. Cardiovasc Res 1996; 32: 752-63.
• 26 Nakajima Y, Baudry N, Duranteau J. et al. Microcirculation in intestinal villi: a comparison between hemorrhagic and endotoxin shock. Am J Respir Crit Care Med 2001; 164: 1526-30.
• 27 Boughton-Smith NK, Evans SM, Laszlo F. et al. The induction of nitric oxide synthase and intestinal vascular permeability by endotoxin in the rat. Br J Pharmacol 1993; 110: 1189-95.
• 28 Eskandari MK, Kalff JC, Billiar TR. et al. LPS-induced muscularis macrophage nitric oxide suppresses rat jejunal circular muscle activity. Am J Physiol 1999; 277: G478-86.
• 29 Evans T, Carpenter A, Kinderman H. et al. Evidence of increased nitric oxide production in patients with the sepsis syndrome. Circ Shock 1993; 41: 77-81.
• 30 Wray GM, Millar CG, Hinds CJ. et al. Selective inhibition of the activity of inducible nitric oxide synthase prevents the circulatory failure, but not the organ injury/dysfunction, caused by endotoxin. Shock 1998; 09: 329-35.
• 31 Szabo C, Southan GJ, Thiemermann C. Beneficial effects and improved survival in rodent models of septic shock with S-methylisothiourea sulfate, a potent and selective inhibitor of inducible nitric oxide synthase. Proc Natl Acad Sci USA 1994; 91: 12472-6.
• 32 Laszlo F, Whittle BJ, Moncada S. Time-dependent enhancement or inhibition of endotoxin-induced vascular injury in rat intestine by nitric oxide synthase inhibitors. Br J Pharmacol 1994; 111: 1309-15.
• 33 Tracey KJ, Fong Y, Hesse DG. et al. Anti-cachectin/ TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 1987; 330: 662-4.
• 34 Abraham E, Laterre PF, Garbino J. et al. Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients. Crit Care Med 2001; 29: 503-10.
• 35 Fisher Jr CJ, Agosti JM, Opal SM. et al. Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med 1996; 334: 1697-702.
• 36 Norman JG, Sutton ET, Franz MS. et al. Maintenance of dynamic microvascular function and structure in a rat model of endotoxic shock by blockade of the interleukin-1 receptor. Shock 1995; 03: 369-75.
• 37 Alexander HR, Doherty GM, Venzon DJ. et al. Recombinant interleukin-1 receptor antagonist (IL-1ra): effective therapy against gram-negative sepsis in rats. Surgery 1992; 112: 188-93.
• 38 Fisher Jr CJ, Dhainaut JF, Opal SM. et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA 1994; 271: 1836-43.
• 39 Opal SM, Fisher Jr CJ, Dhainaut JF. et al. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis:a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med 1997; 25: 1115-24.